Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region
Table 3
Comparison of C. difficile from LabA (number (%)).
2008 ()
2013
HA-CDI ()
CA-CDI ()
NAP designation
NAP1
22 (40.7)
4 (10.5)
4 (13.3)
NAP4
10 (18.5)
11 (28.9)
4 (13.3)
NAP6
2 (3.7)
3 (7.9)
5 (16.7)
Other
7 (13.0)
5 (13.2)
2 (6.7)
None
13 (24.1)
15 (39.5)
15 (50.0)
Toxin gene presence
A+ B+, CDT+
24 (44.4)
6 (15.8)
9 (30.0)
A+ B+, CDT−
27 (50.0)
31 (81.6)
21 (70.0)
A− B+, CDT+
3 (5.6)
1 (2.6)
0
tcdC genotype
Wildtype
27 (50.0)
29 (76.3)
21 (70.0)
−19
22 (40.7)
7 (18.4)
9 (30.0)
−18
2 (3.7)
0
0
≥−37
3 (5.6)
2 (5.3)
0
Susceptibility
Metronidazole
54 (100)
38 (100)
30 (100)
Vancomycin
54 (100)
38 (100)
30 (100)
Clindamycin
15 (27.8)
11 (28.9)
4 (13.3)
2008 distribution: 2 NAP2, 3 NAP7, and 2 NAP10; 2013 distribution: 1 NAP7 (HA-CDI), 4 NAP10 (2 HA-CDI, 2 CA-CDI), and 2 NAP11 (HA-CDI). CA-CDI: Community-associated Clostridium difficile infections; HA-CDI: Hospital-associated Clostridium difficile infections; NAP: North American pulsotype.
